Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].

Magyar onkologia - 1 Dec 2014

Sárosi Veronika, Balikó Zoltán

Abstract excerpt

Therapy of patients with advanced NSCLC has lately changed due to the algorithm based on the presence or absence of oncogenic mutations. There is an agreement nowadays that in the presence of activating EGFR mutations, the administration of EGFR TKI (gefitinib, erlotinib, afatinib) is the most efficacious initial treatment. Unlike the first-generation TKIs, afatinib is a new, irreversible ErbB blocker,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Cisplatin
Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamates

Share to Guanine

Share to Pemetrexed

Share to Quinazolines

Share to Randomized Controlled Trials as Topic

Source

Identifiers

PMID: 25517450

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].PMID 25517450Read ↗

[Evidence on afatinib in patients progressing on a first-line treatment].Semantic proximity Read ↗

Afatinib for the treatment of advanced non-small-cell lung cancer.Semantic proximity Read ↗

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Semantic proximity Read ↗

Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.Semantic proximity Read ↗

Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.Semantic proximity Read ↗

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.Semantic proximity Read ↗

Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.Semantic proximity Read ↗

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.Semantic proximity Read ↗

First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.Semantic proximity Read ↗

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.Semantic proximity Read ↗

Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.Semantic proximity Read ↗

[Afatinib as first-line therapy in mutation-positive EGFR. Results by type of mutation].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.